Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • ADI-PEG 20: Phase Ib started

    Polaris Pharmaceuticals Inc., San Diego, Calif. Product: ADI-PEG 20 Business: Cancer Molecular target: NA Description: Arginine deiminase (ADI) formulated with polyethylene glycol Indication: Treat advanced pancreatic …

    Published on 12/22/2014
  • ATTCK20: Phase I started

    Unum Therapeutics Inc., Cambridge, Mass. Product: ATTCK20 Business: Cancer Molecular target: CD20 Description: Antibody-targeted tumor cell killing (ATTCK) therapy uses a combination of autologous T-lymphocytes …

    Published on 12/22/2014
  • cAd3-EBO Z: Phase I started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. National Institutes of Health, Bethesda, Md. Product: cAd3-EBO Z Business: Infectious Molecular target: NA Description: Recombinant chimpanzee adenovirus type 3 (…

    Published on 12/22/2014
  • CVT-301: Phase III started

    Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Product: CVT-301 Business: Neurology Molecular target: NA Description: Inhaled formulation of levodopa delivered via Acordas Arcus inhalation technology Indication: …

    Published on 12/22/2014
  • Desmoteplase: Development discontinued

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Desmoteplase (DPSA) Business: Neurology Molecular target: Plasminogen Description: Genetically engineered fibrin-…

    Published on 12/22/2014
  • Gantenerumab: Phase II/III discontinued

    MorphoSys AG (Xetra:MOR; Pink:MPSYF), Martinsried, Germany Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Gantenerumab (R1450, RG1450) Business: …

    Published on 12/22/2014
  • Glembatumumab vedotin: Phase II started

    Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham, Mass. Product: Glembatumumab vedotin (CDX-011) (formerly CR011-vcMMAE) Business: Cancer Molecular target: Glycoprotein NMB (GPNMB); Tubulin Description: Human mAb …

    Published on 12/22/2014
  • GMI-1271: Phase I started

    GlycoMimetics Inc. (NASDAQ:GLYC), Gaithersburg, Md. Product: GMI-1271 Business: Hematology Molecular target: E selectin (SELE) (CD62E) Description: Inhibitor of E selectin (SELE; CD62E) Indication: Treat serious …

    Published on 12/22/2014
  • Herpes simplex virus type 2: Completed Phase I/II enrollment

    Vical Inc. (NASDAQ:VICL), San Diego, Calif. Product: Herpes simplex virus type 2 (HSV-2) vaccine (Vaxfectin-formulated plasmid DNA HSV-2 vaccine) Business: Infectious Molecular target: Not applicable Description: DNA …

    Published on 12/22/2014
  • IW-9179: Phase IIa started

    Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), Cambridge, Mass. Product: IW-9179 Business: Gastrointestinal Molecular target: Guanylate cyclase C (GCC) (GUCY2C) Description: Guanylate cyclase C (GCC; GUCY2C) agonist …

    Published on 12/22/2014
  • MVA-BN Filo: Phase I started

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: MVA-BN Filo Business: Infectious Molecular target: NA Description: Modified vaccinia Ankara (MVA) …

    Published on 12/22/2014
  • ProstVac rilimogene galvacirepvec: Completed Phase III enrollment

    Bavarian Nordic A/S (CSE:BAVA), Kvistgaard, Denmark Product: ProstVac rilimogene galvacirepvec Business: Cancer Molecular target: Not available Description: Vaccine targeting PSA that also contains a Tricom triad of …

    Published on 12/22/2014
  • Talimogene laherparepvec: Phase Ib/II started

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: Talimogene laherparepvec (formerly OncoVEX GM-CSF) Business: Cancer Molecular target: NA Description: Modified herpes simplex virus type 1 (HSV-1) encoding GM-CSF…

    Published on 12/22/2014
  • AKB-9778: Completed Phase II enrollment

    Aerpio Therapeutics Inc., Cincinnati, Ohio Product: AKB-9778 Business: Ophthalmic Molecular target: Protein tyrosine phosphatase receptor type D (PTPRD) (HPTP) beta Description: Tyrosine kinase receptor 2 (Tie2) …

    Published on 12/15/2014
  • Aldoxorubicin: Phase III hold

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 12/15/2014
  • Anti-HER2-ADC: Phase I started

    Synthon Beta.V., Nijmegen, the Netherlands Product: Anti-HER2-ADC (SYD985) Business: Cancer Molecular target: Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (neu) Description: Antibody-drug conjugate (ADC) …

    Published on 12/15/2014
  • C-Cure: Phase III start

    Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium Product: C-Cure (C3BS-CQR-1) Business: Cardiovascular Molecular target: NA Description: Cellular therapy based on autologous stem cells …

    Published on 12/15/2014
  • CL-108: Phase III started

    Charleston Laboratories Inc., Jupiter, Fla. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: CL-108 Business: Neurology Molecular target: NA Description: Bilayered tablet containing 12.5 mg immediate-release …

    Published on 12/15/2014
  • CL-108: Phase III started

    Charleston Laboratories Inc., Jupiter, Fla. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: CL-108 Business: Neurology Molecular target: NA Description: Bilayered tablet containing 12.5 mg immediate-release …

    Published on 12/15/2014
  • ELAD system: Phase III started

    Vital Therapies Inc. (NASDAQ:VTL), San Diego, Calif. Product: ELAD system Business: Hepatic Molecular target: NA Description: Human liver cell-based extracorporeal liver assist device (ELAD) Indication: Treat severe …

    Published on 12/15/2014
  • Gevokizumab: Phase III started

    Xoma Corp. (NASDAQ:XOMA), Berkeley, Calif. Servier, Neuilly-sur-Seine, France Product: Gevokizumab (S 78989, XOMA 052) Business: Dermatology Molecular target: Interleukin-1 (IL-1) beta Description: Humanized IgG2 mAb …

    Published on 12/15/2014
  • ISIS-SMNRx: Phase III started

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Product: ISIS-SMNRx Business: Neurology Molecular target: Survival of motor neuron 2 centromeric (SMN2) Description: Antisense oligonucleotide that modulates …

    Published on 12/15/2014
  • ITI-007: Phase III started

    Intra-Cellular Therapies Inc. (NASDAQ:ITCI), New York, N.Y. Product: ITI-007 Business: Neurology Molecular target: Serotonin (5-HT2A) receptor; Dopamine receptor Description: Dual serotonin (5-HT2A) receptor antagonist …

    Published on 12/15/2014
  • LY3314814: Phase II/III started

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: LY3314814, AZD3293 Business: Neurology Molecular target: Beta-site APP-cleaving enzyme 1 (BACE1); Beta-site APP…

    Published on 12/15/2014
  • MyeloXen: Phase I/IIa ongoing

    Xenetic Biosciences Inc. (OTCBB:XBIO), Lexington, Mass. Pharmsynthez JSC (MICEX:LIFE), St. Petersburg, Russia Product: MyeloXen Business: Autoimmune Molecular target: Myelin basic protein (MBP) Description: Liposomal …

    Published on 12/15/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993